Sawa Chika, Yofu Sachiko, Kiriyama Keisuke, Sutoh Keita, Saito Tomomi, Kishi Satomi, Gunji Mariko, Inoue Yuriko, Sugi Masahito, Shioda Seiji, Honda Kazuho
Department of Anatomy, Showa University, School of Medicine, Tokyo, Japan.
Department of Dermatology, Showa University, School of Medicine, Tokyo, Japan.
Heliyon. 2021 Nov 6;7(11):e08318. doi: 10.1016/j.heliyon.2021.e08318. eCollection 2021 Nov.
Tumor necrosis frequently occurs in malignant tumors, showing rapid growth and invasion. This phenomenon is generally regarded as simple ischemic necrosis due to insufficient tumor vessels and blood supply. However, the necrotic tissue contains high amount of nuclear substances, DNA, and nucleoproteins that may affect the surrounding tumor cells by promoting or suppressing the tumor cell growth . This study focused on the effects of an externally administered water-soluble nuclear crude extract (SNE) containing nuclear protein and oligonucleotides on several human cancer and noncancer cell lines. The results demonstrated that the SNE suppressed cell growth in cancer and noncancer cells . Through the flow cytometry analysis of the nuclear DNA content, it was observed that the SNE increased and decreased cell proportion in the S and G2/M phases, respectively, thereby suggesting that the cell growth inhibition was due to cell cycle delay, and not due to apoptosis. These studies suggest that the high-concentration of extracellular nucleotides generated as a result of tumor necrosis and/or released from infiltrated neutrophils could suppress the growth of surrounding cancer and intrinsic cells, which provides us some insights into an alternative anticancer strategy for patients with highly malignant necrotic tumor.
肿瘤坏死在恶性肿瘤中经常发生,表现为快速生长和侵袭。这种现象通常被认为是由于肿瘤血管和血液供应不足导致的单纯缺血性坏死。然而,坏死组织含有大量的核物质、DNA和核蛋白,这些物质可能通过促进或抑制肿瘤细胞生长来影响周围的肿瘤细胞。本研究聚焦于含有核蛋白和寡核苷酸的外用水溶性核粗提物(SNE)对几种人类癌细胞系和非癌细胞系的影响。结果表明,SNE抑制癌细胞和非癌细胞的生长。通过对核DNA含量的流式细胞术分析,观察到SNE分别增加和减少了S期和G2/M期的细胞比例,从而表明细胞生长抑制是由于细胞周期延迟,而不是由于凋亡。这些研究表明,肿瘤坏死和/或浸润的中性粒细胞释放产生的高浓度细胞外核苷酸可以抑制周围癌细胞和固有细胞的生长,这为我们为高度恶性坏死性肿瘤患者提供了一种替代抗癌策略提供了一些见解。